Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF "ADALIMUMAB SOLUTION FOR INJECTION" FOR MARKETING2022.01.20
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE FIRST GENERIC "SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE SUSTAINED-RELEASE TABLETS" FOR MARKETING2022.01.10
-
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 20212022.01.03
-
NEXT DAY DISCLOSURE RETURN2021.12.29
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2021.12.29
-
VOLUNTARY ANNOUNCEMENT - INNOVATIVE MEDICINE "TCR1672" OBTAINED APPROVAL FOR CLINICAL TRIAL2021.12.21
-
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE SALES AGREEMENT OF PENPULIMAB MONOCLONAL ANTIBODY2021.12.20
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2021.12.07